Autolus Therapeutics plc (AUTL)
| Market Cap | 500.39M +36.2% |
| Revenue (ttm) | 117.39M +292.2% |
| Net Income | -280.16M |
| EPS | -1.05 |
| Shares Out | 266.16M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,724,832 |
| Open | 1.980 |
| Previous Close | 1.960 |
| Day's Range | 1.870 - 1.980 |
| 52-Week Range | 1.175 - 2.580 |
| Beta | 2.09 |
| Analysts | Strong Buy |
| Price Target | 8.73 (+364.36%) |
| Earnings Date | Aug 11, 2026 |
About AUTL
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in ph... [Read more]
Financial Performance
In 2025, Autolus Therapeutics's revenue was $75.39 million, an increase of 644.94% compared to the previous year's $10.12 million. Losses were -$287.53 million, 30.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for AUTL stock is "Strong Buy." The 12-month stock price target is $8.73, which is an increase of 364.36% from the latest price.
News
Autolus Therapeutics granted RMAT designation for obecabtagene autoleucel
Autolus Therapeutics (AUTL) announced that the FDA has granted regenerative medicine advanced therapy, or RMAT, designation to obecabtagene autoleucel for the treatment of systemic lupus erythematosus...
Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
LONDON and GAITHERSBURG, Md., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-gen...
Autolus Therapeutics Slides: Corporate presentation
Autolus Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 18, 2026.
Autolus Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 saw robust revenue growth and margin expansion, driven by strong AUCATZYL sales and operational efficiencies. Guidance was raised, cash runway extended, and multiple clinical milestones are expected in 2027–2028.
Autolus Therapeutics Earnings release: Q2 2026
Autolus Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Autolus Therapeutics Slides: Q2 2026
Autolus Therapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 11, 2026.
Autolus Therapeutics Quarterly report: Q2 2026
Autolus Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
Autolus Therapeutics raises FY26 revenue view to $140M-$150M from $120M-$135M
Coonsensus $139.42M. The company said, “Autolus recently increased the full year 2026 guidance for AUCATZYL net product revenue to $140 million to $150 million, from between $120 million to $135…
Autolus Therapeutics reports Q2 EPS (15c), consensus (19c)
Reports Q2 revenue $45.69M, consensus $40.15M. “In the second quarter we achieved substantial sales growth in the ongoing AUCATZYL launch, driven by physician enthusiasm and expanding product use with...
Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026
LONDON and GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-gene...
Autolus Therapeutics reports preliminary Q2 revenue $45M, consensus $29.86M
“In the second quarter, AUCATZYL sales increased approximately 70% over Q1 2026 and more than 100% compared to Q2 2025. The strong sales growth is driven by expanding product use…
Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors
Company reports preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million and gross margin of approximately 35% year-to-date FY 2026 sales guidance increased to $140 – $150 million...
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LONDON & GAITHERSBURG, Md., July 01, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-genera...
Autolus Therapeutics Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
A differentiated CAR T-cell therapy shows strong safety and efficacy in real-world and clinical settings, with expanding adoption and revenue growth. Ongoing studies target broader oncology and autoimmune indications, with key data readouts expected through 2028.
Autolus Therapeutics to Participate in Upcoming Investor Conference
LONDON and GAITHERSBURG, Md., June 25, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-gene...
Autolus Therapeutics Receives Prix Galien UK Award
LONDON and GAITHERSBURG, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-gene...
Autolus Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Strong U.S. launch and expanding adoption of the lead CAR-T product are driving revenue growth, with real-world data confirming high efficacy and safety. International expansion is underway, and margin positivity was achieved ahead of schedule, while clinical programs in pediatric, frontline, and autoimmune indications continue to advance.
Autolus Therapeutics Transcript: 46th Annual William Blair Growth Stock Conference
Market leadership achieved in relapsed/refractory acute leukemia with strong revenue growth and positive gross margin. Pipeline advances include pivotal studies in pediatric leukemia, lupus nephritis, and MS, with real-world data confirming high remission rates and safety.
Autolus Therapeutics to Participate in Upcoming Investor Conferences
LONDON and GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-gener...
Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-gener...
Autolus Therapeutics Slides: Corporate presentation
Autolus Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 21, 2026.
Autolus Therapeutics price target raised to $10 from $9 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Autolus Therapeutics (AUTL) to $10 from $9 and keeps a Buy rating on the shares post the Q1 report. The firm says…
Autolus Therapeutics reports Q1 EPS (27c), consensus (26c)
Reports Q1 revenue $26.22M, consensus $26.13M. “In the first quarter, Autolus continued to expand market share for AUCATZYL in the US based on strong physician experience in adult ALL, and…
Autolus Therapeutics backs FY26 revenue view $120M-$135M, consensus $129.39M
The company said, “Autolus reiterates its full year 2026 outlook for AUCATZYL net product revenue of between $120 million to $135 million, up from $74 million in 2025, as well…
Autolus Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw strong revenue growth, first positive gross margin, and expanding U.S. and U.K. market penetration. Guidance for 2026 revenue is unchanged, with operational improvements and clinical pipeline progress supporting long-term growth and profitability targets.